The platform works well, messaging is responsive, and fulfillment is fast
The analog has a lot of potentials to evolve into a new anti-diabetic and/or anti-obese contender based on its in vitro and in vivo characteristics [22]
The work you put in now might help you spot a great opportunity in two or three years time
in June 2024
The Policy: Medicare's BALANCE Model In July 2026, Medicare launches the GLP-1 Bridge, an interim six-month pilot covering semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for beneficiaries with a BMI of 30 or higher, or BMI of 27 or higher with an obesity-related comorbidity (diabetes, cardiovascular disease, hypertension)
2023 Phase 2 obesity trial and produced approximately 24% mean weight loss at 48 weeks, but with a clearly higher gastrointestinal adverse-event burden than 8 mg [5][2]